4/5
09:32 am
ngm
NGM Bio Announces Closing of Tender Offer [Yahoo! Finance]
Neutral
Report
NGM Bio Announces Closing of Tender Offer [Yahoo! Finance]
4/5
09:19 am
ngm
NGM Bio Announces Closing of Tender Offer
Neutral
Report
NGM Bio Announces Closing of Tender Offer
3/22
01:34 pm
ngm
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm
Neutral
Report
Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm
3/21
03:30 am
ngm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/20
07:00 am
ngm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/19
05:36 pm
ngm
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting [Yahoo! Finance]
Low
Report
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting [Yahoo! Finance]
3/19
05:30 pm
ngm
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
Low
Report
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
3/19
03:30 am
ngm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/18
03:30 am
ngm
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/14
01:30 pm
ngm
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/13
01:01 pm
ngm
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM
3/13
11:44 am
ngm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
Low
Report
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
3/12
05:45 pm
ngm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/12
08:01 am
ngm
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
3/11
07:01 pm
ngm
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
3/11
04:27 pm
ngm
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/11
04:05 pm
ngm
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
Neutral
Report
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
3/11
03:30 am
ngm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Neutral
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
3/7
10:50 am
ngm
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season [Yahoo! Finance]
Neutral
Report
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season [Yahoo! Finance]
3/5
04:18 pm
ngm
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, MDC, NGM, JNPR
Low
Report
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, MDC, NGM, JNPR
3/4
05:00 pm
ngm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
2/29
07:35 am
ngm
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating.
Low
Report
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating.
2/28
07:30 am
ngm
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at TD Cowen from an "outperform" rating to a "market perform" rating.
Low
Report
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at TD Cowen from an "outperform" rating to a "market perform" rating.
2/27
04:10 pm
ngm
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
Medium
Report
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
2/27
09:17 am
ngm
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating.
Medium
Report
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating.